Skip to main content
Figure 2 | Annals of Surgical Innovation and Research

Figure 2

From: Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding

Figure 2

Variability in time to hemostasis (TTH) after treatment with different concentrations of rThrombin or placebo. TTH was measured in the rabbit AV shunt model of anastomotic bleeding after treatment with heparin + clopidogrel. PTFE graft segments were punctured, and AGS containing 1000 IU/mL or 125 IU/mL of rThrombin or placebo was applied to the bleeding site. The TTH observation period extended from 60 seconds to 300 seconds, as indicated by the dashed lines. Each diamond represents the TTH value for a single graft. Four grafts in the placebo group had not achieved hemostasis at the end of the observation period and are not included in the graph (i.e. 4 TTH values were > 300 seconds). All grafts treated with 125 IU/mL or 1000 IU/mL rThrombin achieved hemostasis within the observation period.

Back to article page